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S U M M A R Y
Tuberculosis (TB) remains a global emergency, with an estimated 9.6 million new TB cases worldwide
reported in 2014. Twenty-eight percent of these cases were in the World Health Organization (WHO)
Africa Region, where the annual case detection rate was 281 per 100 000 population—more than double
the global average of 133 per 100 000. Of the 9.6 million people who developed TB, an estimated
1.2 million (12%) were HIV-positive, and the Africa Region accounted for 74% of these cases. Three million
people with TB remain undiagnosed and untreated. Globally, an estimated 480 000 had multidrug-
resistant TB (MDR-TB). Whilst of the African countries, only South Africa has reported a high prevalence
of MDR-TB, it is likely that all of Sub-Saharan Africa has an unreported high load of drug-resistant TB.
Tragically, in 2014, only 48% of individuals diagnosed with MDR-TB had successful treatment and an
estimated 190 000 people died of MDR-TB. Of the global TB funding gap of US$ 0.8 billion, the largest
funding gap was in the Africa Region, amounting to US$ 0.4 billion in 2015. The MDR-TB pandemic in
particular now threatens to devastate entire regions and may fundamentally alter the life-expectancy
and demographic proﬁle of many countries in Sub-Saharan Africa. The theme designated for this year’s
World TB Day, March 24, 2016, is ‘Unite to End TB’. From the Africa Region, there is an urgent need to
seriously address the political, economic, and social factors that inﬂuence host–Mycobacterium
tuberculosis interactions and result in disease. Recent political and funder initiatives that provide
renewed hope for the alleviation of Africa’s TB and TB/HIV problems are discussed.
 2016 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j idTuberculosis (TB) has remained a global emergency ever since it
was declared as such by the World Health Organization (WHO) in
1993.1 The theme designated for this year’s World TB Day, March* Corresponding author.
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creativecommons.org/licenses/by-nc-nd/4.0/).24, 2016, is ‘Unite to End TB’.2 World TB Day is held to
commemorate the day in 1882 when Professor Robert Koch
announced his ground-breaking discovery of the cause of TB, the
bacillus Mycobacterium tuberculosis.3 At the time of Koch’s
announcement in Berlin, TB was widespread and rampaging
through Europe and the Americas, causing the death of one out of
every seven people.4 Over the ensuing 60 years, TB rates in Europeious Diseases. This is an open access article under the CC BY-NC-ND license (http://
F. Ntoumi et al. / International Journal of Infectious Diseases 46 (2016) 34–37 35and the USA started to decline, well before the advent of TB drugs
and the bacillus Calmette–Gue´rin (BCG) vaccine, highlighting the
fact that TB epidemics are driven by complex socio-economic
factors and host–M. tuberculosis interactions.4–11
It has been 134 years since Professor Koch’s discovery of
M. tuberculosis, and yet today TB remains the most common cause
of death from an infectious disease worldwide.1 According to the
2015 WHO Annual TB Report, an estimated 1.5 million people died
of TB out of 9.6 million people who developed active TB worldwide
in 2014.12 Of these 9.6 million TB cases, 28% were in the WHO
Africa Region, where the incidence rate was 281 new TB cases per
100 000 population. This is more than double the global average
rate of 133 per 100 000.12 An estimated 1.2 million out of the
9.6 million TB cases (12%) were HIV-positive and the Africa Region
accounted for 74% of them. It is important to note that in 2014,
three million people with TB went undiagnosed and untreated, or
unreported. A signiﬁcant proportion of these were in Sub-Saharan
African countries. Critical to reducing the global burden of TB and
slowing down TB transmission rates is the identiﬁcation and
treatment of all active cases of pulmonary TB, rendering them non-
infectious.13 Furthermore, those individuals with a high risk of re-
activation of latent TB infection need to be identiﬁed and treated.12
While the overall global incidence of TB has been declining slowly
over the past decade, drug-resistant strains of M. tuberculosis have
emerged worldwide. Tragically, in 2014, an estimated 190 000 peo-
ple died of multidrug-resistant TB (MDR-TB),12 and only 48% of
the 480 000 people estimated by the WHO to have MDR-TB had
received successful treatment. The number of MDR-TB cases in
2014 remained unchanged from the ﬁgure estimated in the previous
year’s 2013 WHO Annual TB Report. This may represent an
underestimate, or could be explained by inadequate laboratory
infrastructure and resources to correctly diagnose and report MDR-
TB at the health facility and national levels. Whilst of the African
countries, only South Africa has reported a high prevalence of MDR-
TB, it is likely that all of Sub-Saharan Africa has a signiﬁcant burden
of unreported drug-resistant TB.
Over the past three decades the world has experienced the most
profound of public health challenges with the appearance of new
infectious pathogens with epidemic potential, such as Ebola virus
(EBOV), severe acute respiratory syndrome coronavirus (SARS-
CoV), Middle East respiratory syndrome coronavirus (MERS-CoV),
and now Zika virus (ZIKV) and antibiotic-resistant bacteria. We
have also seen the resurgence of malaria, TB, and other infectious
diseases, which were being brought under control.14 We have also
witnessed the emergence of the devastating HIV pandemic, which
has largely been responsible for the breakdown of TB control
programs. Together, TB and HIV have imparted a huge toll on
health services and the economies of Sub-Saharan African
countries.15 The MDR-TB pandemic in particular now threatens
to devastate entire regions and may fundamentally alter the life-
expectancy and demographic proﬁle of many African countries.16
There is an urgent need to address priority needs for MDR-TB,16
especially in Africa, where resources and capacity are limited. MDR-
TB has relevance beyond the worst affected countries, since TB does
not respect national or international borders. The number of people
forced to ﬂee their homeland due to conﬂicts or natural disasters in
the past few years has reached an all-time high worldwide.17 A large
number of refugees are being cared for in low- and middle-income
countries. Furthermore the large funding gap (difference between
the actual funding needs of TB programs for TB prevention,
diagnosis, and treatment and the actual amount of funds available)
for the Africa Region was US$ 0.4 billion in 2015.12
The WHO post-2015 global TB strategy aims to reduce global TB
incidence by 90% before 2035.18 However, the data in the
2015 WHO Annual TB Report show a bleak global TB situation.
Dr Lucica Ditiu, Executive Director of the Stop TB Partnership, aptlysummarized the situation recently by stating ‘‘It is a global disgrace
and human tragedy that TB—a curable disease—is killing around
1.5 million people per year and nobody speaks about ending it’’,
and further ‘‘We know it can be done, we know how it can be done,
we know how much it will cost us—we need to have the desire to
do it and energy to move on. Ours can be the generation
remembered as the one that turned the tide on this enormous
yet treatable epidemic.’’19
The Global Plan to End TB 2016–2020 launched by the Stop TB
Partnership has three fundamental targets called 90–(90)–90:19
 Aim 1 is to have 90% of all people with TB diagnosed and treated.
 Aim 2 (which is coupled to aim 1) is to ensure that 90% of the
most vulnerable populations in all countries (high- and low-
income) are diagnosed and treated; these populations would
include children, people living with HIV, miners, addictive
substance users, prisoners, the homeless, and migrants, as well as
others – we would like to include healthcare workers and patient
carers in this list.
 Aim 3 is to ensure that 90% of people diagnosed successfully
complete treatment with services to ensure adherence and social
support.
In addition, the Global Plan calls for an additional US $9 billion
for research and development into improved diagnostics, treat-
ment regimens, and vaccines that are highly effective and non-
toxic. The current funding trends for TB research have been rather
disappointing.20 In the Africa Region, there is also an urgent need to
seriously address the political, economic, and social factors, apart
from HIV, that inﬂuence host–M. tuberculosis interactions and
increase the risk of developing active TB, or re-activation of latent
TB infection, and result in poor treatment outcomes.7–9
So what more can researchers, healthcare workers, communi-
ty groups, governments, the private sector, non-governmental
organizations (NGOs), and funders do to effect a major shift from
the current status quo with regard to global TB and TB/HIV control
efforts in Africa? To achieve the laudable and ambitious 90–(90)–
90 aims, the global scientiﬁc, political, and funder communities
seriously need to ‘Unite to End TB’,21 and heed calls to action that
have regularly been repeated on World TB Day5–11 for the scaling
up of TB services for the improved diagnosis, management, and
control of TB.22
Recent political and funder initiatives have provided new hope
for the WHO Africa Region to reduce the burden of TB and TB/HIV.
Several novel and encouraging initiatives now present opportu-
nities for the Sub-Saharan African scientiﬁc and political commu-
nities to engage more proactively in galvanizing resources,
conducting priority scientiﬁc and operational research, and
facilitating national TB program control efforts, and thereby to
take forward boldly the aims of the Global Plan to End TB in Africa.
Examples of these are the following:
(1) The European Union supported EDCTP2 program (European
and Developing Countries Clinical Trials Partnership), which
provides unique opportunities for developing equitable,
European–African partnerships in clinical research, capacity
development, and training on poverty-related diseases, includ-
ing TB and TB/HIV.23–25
(2) The Global TB Caucus, a formidable network of parliamentar-
ians and political representatives from over 100 countries.26
(3) An African network called WARN-TB, which works with the
WHO Tropical Disease Research Program (WHO-TDR) and
plans to develop new approaches that will increase the
numbers of people diagnosed and treated, build capacity for
TB operational research, and support resource mobilization for
TB control.27
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to mobilize political will, ﬁnancial commitments from donors,
and governments of MDR-TB endemic countries.28
(5) The expansion of Africa-based grassroots community initia-
tives: (a) The ENGAGE-TB approach, where the ﬁve founder
countries (the Democratic Republic of the Congo, Ethiopia,
Kenya, South Africa, and the United Republic of Tanzania) have
been joined by Burkina Faso, Coˆte d’Ivoire, Malawi, Namibia,
and Zimbabwe.29 (b) Increasing activities of community TB
groups like TB Proof,30 which was founded in 2012 by African
health care workers and students after suffering multiple
personal experiences with MDR-TB,31,32 and increased the
commitment of 90 non-governmental and other civil society
organizations from 35 African countries to the WHO End TB
Strategy.33
(6) The United States Agency for International Development
(USAID) ‘‘Challenge TB Award’’ to ﬁght TB, a 5-year cooperative
agreement to implement the USAID global TB strategy.34
These, and other initiatives, now offer unique opportunities and
motivation for African scientists, healthcare workers, and govern-
ments to ‘Unite to End TB’. A recently published book entitled
‘‘African health leaders—making a change and claiming the
future’’,35 contains important and relevant messages for the TB
and TB/HIV fraternity in Sub-Saharan Africa. This book was edited
by Professor Francis Omaswa and Lord Nigel Crisp, Chairman of the
UK All Party Parliamentary Group on Global Health, a tireless
advocate for global health and international development issues
and renowned for his commitment to improving health services in
Africa. It contains chapters written by three generations of African
leaders, including the ex-Prime Minister of Mozambique, Dr
Pascoal Mocumbi, and Rwandan Minister of Health, Dr Agnes
Binagwaho, among others who have led the transformation of
health services in Africa. They detail their experiences and vision
for Africa health systems, emphasizing that ‘‘African leaders and
leadership in health have an enormous role to play in a new Africa,
where Africans recognize that the responsibility for making Africa
an equal player in the global community rests primarily with
Africans.’’ They address key global health issues and emphasize
that there are lessons that other nations can learn from Africa. In
addition, they challenge Africans to take up the mantle and lead
from the front. This supports the repeated calls for Africa to
become independent from the dominance of research in Africa by
Western institutions,36–38 and to build infrastructure and capabili-
ty that can be sustained in the long term.
The second program of the European and Developing Countries
Clinical Trials Partnership (EDCTP2)23,38 now provides unique
opportunities over the next 10 years for African scientists to take
up leadership on poverty-related diseases including TB and to
develop equitable north–south clinical trials research and training
partnerships based on priority issues. EDCTP2 has substantial
funding for clinical trials research, training, and capacity develop-
ment on TB as one of the major poverty-related diseases in Sub-
Saharan Africa.25 Three funding schemes or ‘actions’ are supported
under the EDCTP2 program:38 (1) research and innovation actions
(RIA), (2) coordination and support actions (CSA), and (3) training
and mobility actions (TMA). RIAs are primarily clinical research
activities and clinical trials conducted in partnership between
European and Sub-Saharan African countries aimed at increasing
the number of new or improved interventions for TB, HIV, malaria,
and other poverty-related diseases. CSAs are primarily accompa-
nying measures, such as activities to develop, strengthen, and
extend clinical research capacities in Sub-Saharan Africa. They aim
to maximize the public health impact of research results by
promoting their translation and supporting their uptake in policy-
making, health systems, and clinical practice at the local, national,regional, and international levels. TMAs are activities that foster
career development (fellowships) of individual junior and senior
researchers from Sub-Saharan Africa, support training and
mentorship of researchers, and promote mobility of individual
researchers. Between 2009 and 2014, EDCTP supported four
African (South, East, West, and Central) regional networks of
excellence,39 which enabled African scientiﬁc leadership to
develop and address capacity development and training needs,
identify gaps for tackling TB, and develop locally relevant solutions.
Progress made under the ﬁrst EDCTP program requires consolida-
tion, and the research capacity built needs to be strengthened
further.
It is important that alongside EDCTP2 and other current donor
initiatives, African governments seriously commit to, and set aside
a speciﬁc budget for, TB research, capacity development, and
control initiatives in their own countries. Furthermore, the
conventional and longstanding focus on promoting the develop-
ment of new TB drugs, diagnostics, and vaccines40 must be
supplemented by novel innovations that focus on the host factors
responsible for and driving the poor treatment outcomes of MDR-
TB treatment. This would include the neglected issue of long-term
functional disability that arises from the permanent lung damage
suffered by a signiﬁcant proportion of TB patients, who recover
after treatment but are unable to lead normal lives or go back to
work.41,42 A whole range of host-directed therapies are now
becoming available. These will require evaluation in clinical trials
for their impact when used as adjunct therapy, on shortening the
duration of TB treatment, improving treatment outcomes of MDR-
TB, and preventing pulmonary damage and functional disability.43
This will be taken forward by a recently formed Host-Directed
Therapies Network consortium (HDT-NET),44 a consortium of
partners from all regions of Africa in collaboration with institutions
in Europe, Australia, and the USA.45
TB control programs in Sub-Saharan Africa can only succeed if
appropriate mechanisms for close engagement of national
scientists, healthcare workers, patient groups, governments, and
policy-makers are put in place. Furthermore, scaling up sustainable
interventions for TB care and treatment requires high-level
political commitment and adequate ﬁnancial and human
resources.46 Central coordination under the national government’s
stewardship will be essential. African governments must step up
current efforts to further improve the quality of proactive TB
screening and identiﬁcation of all missed, sub-clinical and
undiagnosed cases of TB,47,48 improve health services to provide
quality TB treatment, and provide follow-up care. Efforts must also
be stepped up to improve capacity for rapidly diagnosing MDR-TB
to address this deadly and growing epidemic in Africa.12 We also
re-iterate that it is only through the empowerment of the
indigenous younger generation scientists, program managers,
and healthcare workers that the current status quo can be changed
signiﬁcantly.
The only way forward to achieve the aims of The Global Plan to
End TB 2016–2020 is for researchers, funders, national govern-
ments, industry, pharma, and community groups to ‘Unite to End
TB’ and promote the four WHO sub-themes for World TB Day,
March 24, 2016: (1) together we can better test, treat, and cure TB,
(2) together we can end TB stigma and discrimination, (3) together
we can drive TB research and innovation, and (4) together we can
prevent TB by ending poverty. All national governments and
funder and donor investments in TB in Africa should be aligned in
parallel with international efforts to improve social and living
conditions and with the ‘one health’ initiative, which provides a
holistic approach to managing poverty-related diseases.49 Only
then will signiﬁcant progress be made in achieving WHO post-
2015 End TB Strategy goals, and gains in achieving TB control will
be enhanced and sustained.
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